6 12, 2017

FDA Support for Treating Opioid Addiction With Medication

By | 2017-12-06T05:03:22+00:00 December 6th, 2017|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

The FDA plans to convene an expert panel to examine the population-level effects of treating opioid addiction with medication in hopes of gaining wider acceptance of and insurance coverage for those medications. During a late October hearing, FDA Commissioner Scott Gottlieb, MD, told the House Committee on Energy and Commerce [...]

5 12, 2017

New Buprenorphine Formulation Approved for Medication-Assisted Opioid Treatment

By | 2017-12-05T10:29:35+00:00 December 5th, 2017|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

The Food and Drug Administration has approved an extended-release, subcutaneous injection formulation of buprenorphine for use in treating moderate to severe opioid use disorder (OUD), the manufacturer of the drug announced recently. The new product, called Sublocade, is a monthly injection intended for use in patients who have already begun [...]

4 12, 2017

ADHD Redux: Overdiagnosed and Overtreated, or Misdiagnosed and Mistreated?

By | 2017-12-04T09:08:38+00:00 December 4th, 2017|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

By Michael J. Manos, Kimberly Giuliano, and Eric Geyer The Affordable Care Act of 2010 sought to transform medical care in the United States from procedures to performance, from acute episodes of illness to integrated care across the lifespan, and from inefficient care to efficient and affordable care with measurable outcomes. At [...]

1 12, 2017

Phase 3 Study of Intepirdine Fails in of Mild to Moderate Alzheimer’s Patients

By | 2017-12-01T16:24:37+00:00 December 1st, 2017|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

An investigational Alzheimer’s drug intended to potentiate acetylcholine release didn’t pass muster in a global phase 3 study, despite a successful phase 2 trial. Intepirdine on a background of stable-dose donepezil failed to confer any cognitive or functional benefit in patients with mild to moderate Alzheimer’s disease. Intepirdine blocks the 5-hydroxytryptamine [...]

30 11, 2017

Facebook to Expand Artificial Intelligence to Help Prevent Suicide

By | 2017-11-30T11:29:58+00:00 November 30th, 2017|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

SAN FRANCISCO (Reuters) - Facebook Inc will expand its pattern recognition software to other countries after successful tests in the U.S. to detect users with suicidal intent, the world's largest social media network said on Monday. Facebook began testing the software in the United States in March, when the company [...]

30 11, 2017

FDA Approves Vraylar for Schizophrenia in Adults

By | 2017-11-30T11:30:29+00:00 November 30th, 2017|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

Allergan plc has announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of adults with schizophrenia. Vraylar is also approved in the US in adults for the acute treatment of schizophrenia and acute treatment of [...]

16 11, 2017

NIMH: Ketamine-Like Hallucinogens May Offer New Hope for Treatment-Resistant Depression

By | 2017-11-16T13:17:35+00:00 November 16th, 2017|Brainscience Blogs|0 Comments

In 2006, psychiatrist Carlos A. Zarate Jr, MD, and colleagues at the National Institute of Mental Health (NIMH) published a seminal finding in Archives of General Psychiatry (now JAMA Psychiatry): A single intravenous dose of ketamine—an anesthetic agent with hallucinogenic properties—produced robust antidepressant effects in patients with treatment-resistant depression (TRD) [...]

15 11, 2017

Digital Tattletales: New Technology Alerts Drug Non-Compliance

By | 2017-11-15T08:03:33+00:00 November 15th, 2017|Brainscience Blogs|0 Comments

The antipsychotic agent, Abilify (aripiprazole, Otsuka), is the first Food and Drug Administration approved digital pill — a medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine. The wearable sensor patch is made by Proteus Digital Health. The approval marks a significant advance in [...]

15 11, 2017

Study Finds Competing Opioid Treatments Same, with One Caveat

By | 2017-11-15T07:41:51+00:00 November 15th, 2017|Brainscience Blogs|0 Comments

A long-awaited study has found that two of the main medications for treating opioid addiction are similarly effective. The study, funded by the federal government, compared Vivitrol, which comes in a monthly shot and blocks the effects of opioids, and Suboxone, which is taken daily in strips that dissolve on the [...]

13 11, 2017

Can an App that Tracks Medication Doses and Mood Swings Help Improve Depression Treatment?

By | 2017-11-13T16:07:19+00:00 November 13th, 2017|Brainscience Blogs|0 Comments

PHARMA NEWS Takeda and Lundbeck are planning a  U.S. test for a depression app that will track mood, in the hopes it will improve depression treatment. The two pharma companies have teamed up with Advocate Health Care on a study that uses an app with a “conversational text interface” to track and [...]